I

n biopharma, patents are everything. In tech? Not so much.

Which is why it was unusual to see a company that’s trying to turn software into medicine announce this week that it’s bagged several patents.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.